Global HER2 Antibodies Market – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

 

Global HER2 Antibodies Market: By Drug Type (Pertuzumab, Trastuzumab, Ado-trastuzumab, emtansine, Lapatinib, Everolimus), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and Geography – Market Estimation, Dynamics, Regional Share, Trends, Competitor Analysis 2013-2017 and Forecast 2018-2024

 

Global HER2 antibodies market was valued at US $ 10.5 Bn in 2017 and expected to grow at 8.5% Compound Annual Growth Rate (CAGR) over the 2018 to 2024.

Market Outline: Global HER2 Antibodies Market

HER2 antibodies are the products used in the treatment of HER2 positive breast cancer. HER2 is the member of human epidermal growth factor family. Over-expression of HER2 oncogene leads to development and progression of certain types of aggressive breast cancer.

 

A sample of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/her2-antibodies-market/#ulp-4H8Z4LpNMLEuOnnx

 

 

 

Market Dynamics: Global HER2 Antibodies Market

Rise in incidence of HER2 positive breast cancer around the globe, rise in R&D for the innovation of newer drugs for HER2 positive breast cancer treatment, promising pipeline products for the treatment, government initiations for breast cancer awareness among the masses, and advanced techniques for HER2 positive breast cancer diagnosis are expected to upsurge the revenue of global HER2 antibodies market over the forecast years. However, high cost of drugs, adverse effects associated with drugs, and fewer produts availability in the market may restrain the growth of global HER2 antibodies market.

To view TOC of this report is available upon request @

https://www.precisionbusinessinsights.com/market-reports/her2-antibodies-market/#ulpc654SbFYO64MsOhu

 

 

 

Market Scope: Global HER2 Antibodies Market

Global HER2 antibodies market is segmented based on drug type and distribution channel

 

Based on the drug type, the market is segmented into the following:

  • Pertuzumab
  • Trastuzumab
  • Ado-trastuzumab emtansine
  • Lapatinib
  • Everolimus

Based on the end user, the market is segmented into the following:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

 

Need more information about this report @

https://www.precisionbusinessinsights.com/market-reports/her2-antibodies-market/#ulp14mlyhjMGhVjZqa3

 

 

 

 

Regional Analysis: Global HER2 Antibodies Market

Geographically, global HER2 antibodies market is segmented into North America, Europe, Asia Pacific, Latin America, and Middle East and Africa. North America HER2 antibodies market growth driven by increase in the prevalence of HER2 positive breast cancer (according to American Cancer Society 2017, about 252,710 women are effected with breast cancer in U.S. with approximately 1 in 5 women are sufferng from HER2 positive breast cancer), rise in R&D for the innovation of newer drugs, and increase in healthcare expenditure. Europe HER2 antibodies market has a lucrative growth opportunities owing to prevalence of HER2 positive breast cancer, high adoption of newer drugs, and regulatory support from cancer associations are expected to bolster the market. However, growth of Asia Pacific HER2 antibodies market driven by rise in medical tourism in Asia Pacific region, advances in healthcare infrastructure for the disease diagnosis, and entry of market players into Asia Pacific region are expected to upsurge the revenue of market.

Competition Assessment: Global HER2 Antibodies Market

Some of the players in the global HER2 antibodies market include:

  • Novartis AG (Switzerland)
  • Pfizer Inc. (U.S.)
  • Biocon Limited (India)
  • Abnova Corporation (Taiwan)
  • Genentech Inc. (U.S.)
  • InvivoGen (U.S.)
  • Bio-Techne Corporation (U.S.)
  • Celltrion Healthcare (South Korea)
  • Puma Biotechnology (U.S.)

Notable Market Developments: Global HER2 Antibodies Market

  • In July 2017, Puma Biotechnology received FDA approval for Nerlynx (Neratinib) to treat early stage HER2 positive breast cancer

 

 

Get access to full summary @

 

https://www.precisionbusinessinsights.com/market-reports/her2-antibodies-market/

 

 

About Precision Business Insights

Precision Business Insights is one of the leading market research and business consulting firm, which follow a holistic approach to solve needs of the clients. We adopt and implement proven research methodologies to achieve better results. We help our clients by providing actionable insights and strategies to make better decisions. We provide consulting, syndicated and customised market research services based on our client needs.

Contact to Precision Business Insights,

Kemp House,

152 – 160 City Road,

London EC1V 2NX

Email: sales@precisionbusinessinsights.com

Toll Free (US): +1-866-598-1553

Website @ https://www.precisionbusinessinsights.com